Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

Gene Therapy

Volumn 4, Issue 8, 1997, Pages 791-796

  Lemmon, M J ^a   Van Zijl, P ^a   Fox, M E ^a   Mauchline, M L ^b   Giaccia, A J ^a   Minton, N P ^b   Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Clostridia; Enzyme producing therapy; Gene therapy; Nitroreductase; Tumor hypoxia

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BACTERIAL DNA; NITROREDUCTASE; PRODRUG;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER THERAPY; CLOSTRIDIUM; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; GENE TARGETING; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT GENE;

ANIMALIA; BACTERIA (MICROORGANISMS); CLOSTRIDIA; CLOSTRIDIUM BEIJERINCKII; ESCHERICHIA COLI;

EID: 0030865697     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300468     Document Type: Article

References (27)

1. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695-712.
2. 2 histography. In: Vaupel PW, Kelleher DK, Gunderoth M (eds). Tumor Oxygenation. Fischer-Verlag: Stuttgart, New York, 1994, pp 219-232.
3. Malmgren RA, Flanigan CC. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955; 15: 473-478.
4. Möse JR, Möse G. Onkolyseversuche mit Apathogenen Anaeroben Sporenb. Academic Press: London, 1982, pp 231-253.
5. Brantner H. The clostridia-tumor phenomenon- fundamentals in oncolytic tumor research. In: Dring GJ, Ellar DJ, Gould GW (eds). Fundamental and Applied Aspects of Bacterial Spores. Academic Press: London, 1985, pp 463-473.
6. Szmigielski S et al. Oncolytic clostridia. In. Jeljaszewicz J, Pulverer G, Roszkowski W (eds). Bacteria and Cancer. Academic Press: London, 1982, pp 231-253.
7. Thiele EH, Arison RN, Boxer GE. Oncolysis by clostridia. IV. Effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res 1964; 24: 234-238.
8. Carey RW et al. Clostridial oncolysis in man. Eur J Cancer 1967; 3: 37-46.
9. Heppner F, Mose J, Ascher PW, Walter G. Oncolysis of malignant gliomas of the brain. 13th Int Cong Chemother 1983; 226: 38-45.
10. Fox ME et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia Gene Therapy 1996; 3: 173-178.
11. Minton NP et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev 1995; 17: 357-364.
12. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB 1954 and its use as a prodrug in. antibody-directed enzyme prodrug therapy (ADEPT). Cancer Met Rev 1993; 12: 195-212.
13. Anlezark GM et al. The bioactivation of 5-(aziridin-1-YL)-2,4-dirutrobenzamide (CB 1954)-I Purification and properties of a nitroreductase enzyme from Escherichia coli-A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992; 44: 2289-2295.
14. Khan AH, Ross WCJ. Tumour growth inhibitory nitrophenyl aziridines and related compounds: structure-activity relationships. Chem Biol Interact 1969/70; 1: 27-47.
15. Knox RJ et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-l-YL)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-l-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988; 37: 4671-1677.
16. Knox RJ et al. The bioactivation of 5-(aziridin-l-YL)-2,4-dinitrobenzamide (CB1954) -II A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992; 44: 2297-2301.
17. Möse JR, Möse G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964; 24: 212-216.
18. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy Br I Cancer 1955; 9: 539-549.
19. Fabricius EM et al. Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous administration. Res Microbiol 1993; 144: 741-753.
20. Deonarain MP, Epenetos AA. Targeting enzymes for cancer therapy: old enzymes in new rolls. Br J Cancer 1994; 70: 786-794.
21. Sunters A, Baer J, Bagshawe KD. Cytotoxicity and activation of CB 1954 in a human tumor cell line. Biochem Pharmacol 1991; 41: 1293-1298.
22. Kashket ER, Cao ZY. Isolation of a degeneration-resistant mutation of Clostridium acetobutylicum NCIMB 8052. Appl Env Microbiol 1993; 59: 4198-4202.
23. Kihm DJ, Hutton MT, Hanlin JH, Johnson EA. Zinc stimulates sporulation in Clostridium botulinum 113B. Curr Microbiol 1988; 17: 193-198.
24. Stevens A. Micro-organisms. In: Bancroft JD, Stevens A, Turner DR (eds). The Theory and Practice of Histological Techniques. 3rd edn. Churchill Livingston: Edinburgh, 1990, p 292.
25. Girard AE et al. Pharmakokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987; 31: 1948-1954.
26. Prochaska HJ. Purification and crystalization of rat liver NAD(P)H:(quinone-acceptor) oxoreductase by cibacron blue affinity chromatography. identification of a new and potent inhibitor. Arch Biochem Biophys 1988; 267: 529-538.
27. Benson AM, Hunkeler MJ, Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 1980; 77: 5216-5220.